Transfection kits and reagents by Category
|
Our customers and collaborators have underscored the importance of providing products and methods that enable improved transfection of primary neurons, other primary cells and cell lines in-vitro and in-vivo. Along with our collaborators, we are providing a variety of products and methods that are enabling researchers to push the boundaries. We will continue to work hard to bring you the transfection reagents needed for your unique applications. For more details, please also visit our Transfection Blog. For information on how siRNA works see Nature Animation.
Image: i-FectTM in action. DOR-immunoreactivity in the dorsal horn of the spinal cord after vehicle, siRNA + i-Fect or mismatch (MM) RNA+ i-Fect treatment. The immunoreactivity of DOR was predominantly found in laminae I/II of the dorsal horn. The immunolabeling was significantly lower in tissue from siRNA + i-Fect treated rats. Tissues taken 72 hours after the last siRNA injection (siRNA recovery) show similar level of immunoreactivity for DOR when compared with vehicle or MM RNA controls. Each image is representative of multiple sections from 3 rats per treatment group. Molecular Pain 2005, 1:29
Image: i-FectTM in action. DOR-immunoreactivity in the dorsal horn of the spinal cord after vehicle, siRNA + i-Fect or mismatch (MM) RNA+ i-Fect treatment. The immunoreactivity of DOR was predominantly found in laminae I/II of the dorsal horn. The immunolabeling was significantly lower in tissue from siRNA + i-Fect treated rats. Tissues taken 72 hours after the last siRNA injection (siRNA recovery) show similar level of immunoreactivity for DOR when compared with vehicle or MM RNA controls. Each image is representative of multiple sections from 3 rats per treatment group. Molecular Pain 2005, 1:29
Transfection kits and reagents by Category | |
| i-Fect ™
A novel cationic lipid formulation specifically designed for efficient delivery of 27mer DsiRNAs(dicer substrate small Interfering RNAs)& 21mer siRNAs (small interfering RNAs) in vitro and in vivo.
| i-Fect ™ Hi Put 96-New
i-Fect based system for high throughput delivery of siRNAs (small interfering RNAs) into a wide variety of cell types.
|
| n-Fect™
A cationic lipid that has been specifically formulated for nervous system applications. n-Fect provides higher transfection efficiency than other commercially available broad-spectrum transfection reagents for glial cells, neuronal cell lines, and certain primary neuronal cultures.
| n-Blast™
A broad-spectrum transfection reagent successfully used in many cell types commonly used by neuroscientists.
|
| p-Fect™
Designed to delivery plasmids, DNA or RNA to hard to transfect Cell Lines.
| pn-Fect™
The latest advance in transfection technology for primary neuronal cells. This unique reagent provides ultra-high plasmid DNA delivery efficiencies and low cytotoxicity compared to competitive reagents.
|
| pro-Fect™
Is a unique lipid-based formulation that allows the delivery of proteins, peptides or other bioactive molecules into a broad range of cell types.
| DNA-Fect™
in vitro DNA-Fect Transfection Reagent contains a patent-pending blend of new gene delivery compounds, which greatly facilitate transfection of DNA to various established cell lines as well as primary cells.
|
| MATra™ Products
Provides a system for Magnetically Driving the transfection process enhancing the performance of transfectants.
| MATra™ Data, Images and Testimonials
Includes Transfection of hepatocyte, Cortical, Cerebrellar, Neuroblastoma, Carcinoma Cells and More
|
| Penetratin-1™
A peptide for delivering small molecules into Neurons and other cells. MP Biomedical is the manufacturer of Penetratin-1
| DsiRNA Transfection Alliance
Optimizing Transfection Using Dicer System siRNA
|
| intra-i-Fect™-NEW
Delivers siRNA intravenously!-tissue specific, easy and fast. Uses proprietary nanoparticle based systems.
| |
No comments:
Post a Comment